We evaluated the performance of the Simplexa Flu A/B & RSV kit on 170 prospective respiratory samples using a modified protocol, supplied by the manufacturer, that eliminates the RNA extraction step. Overall, compared against our laboratory-developed assay, the assay's sensitivity, specificity, and positive and negative predictive values were 95.1%, 99.6%, 98.7%, and 98.6%, respectively.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697722 | PMC |
| http://dx.doi.org/10.1128/JCM.00286-13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Rapid and accurate diagnosis of influenza virus (Flu) and respiratory syncytial virus (RSV) is important for managing both the patient and laboratory. We compared the cobas Influenza A/B & RSV assay (cobas Liat) with the Simplexa Flu A/B & RSV assay (Simplexa) to evaluate which test method is more advantageous considering the resources of the laboratory and results of test performance.
Methods: A total of 236 respiratory specimens from patients referred for respiratory virus testing were retrospectively evaluated; 53 specimens tested positive for each of Flu A, Flu B, and RSV, and 77 specimens tested negative based on the results of the reference method, i.
Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Test.
J Clin Microbiol
February 2021
Cepheid, Sunnyvale, California, USA
With the approach of respiratory virus season in the Northern Hemisphere, clinical microbiology and public health laboratories will need rapid diagnostic assays to distinguish severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from influenza virus and respiratory syncytial virus (RSV) infections for diagnosis and surveillance. In this study, the clinical performance of the Xpert Xpress SARS-CoV-2/Flu/RSV test (Cepheid, Sunnyvale, CA, USA) for nasopharyngeal swab specimens was evaluated in four centers: Johns Hopkins Medical Microbiology Laboratory, Northwell Health Laboratories, NYC Public Health Laboratory, and Los Angeles County/University of Southern California (LAC+USC) Medical Center. A total of 319 nasopharyngeal swab specimens, positive for SARS-CoV-2 ( = 75), influenza A virus ( = 65), influenza B virus ( = 50), or RSV ( = 38) or negative ( = 91) by the standard-of-care nucleic acid amplification tests at each site, were tested using the Cepheid panel test.
View Article and Find Full Text PDFPerformance of the Influ a + B K-SeT® assay as compared to two RT-PCR assays for detection of influenza virus.
Diagn Microbiol Infect Dis
September 2020
Clinical Microbiology Laboratory, Baruch Padeh Medical Center, Poriya, 15208, Israel. Electronic address:
Objectives: To evaluate the performance of Influ A + B K-SeT®, a rapid influenza antigen detection kit, in order to determine whether its implementation as a point-of-care test in the emergency room (ER) is justified.
Methods: Nasopharyngeal swabs (n = 170) were collected in triplicates from patients with suspected influenza infection. One sample was tested by the Influ A + B K-SeT® kit and the other two samples were analyzed with Simplexa™ Flu A/B & RSV Direct Kit and Xpert® Flu, two RT-PCR-based assays routinely used in the ER.
Comparative analysis of Four sample-to-answer influenza A/B and RSV nucleic acid amplification assays using adult respiratory specimens.
J Clin Virol
September 2019
Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, Missouri, USA.
Background: The use of Sample-to-answer (STA) platforms for the detection of influenza A/B and respiratory syncytial virus (RSV) have greatly improved patient care. These diagnostic assays based on nucleic acid amplification are rapid, accurate and relatively easy to perform.
Objectives: We compared four such platforms for detecting FluA, FluB, and RSV from adult respiratory specimens: Hologic Panther Fusion® Flu A/B/RSV (Fusion), Cobas® Influenza A/B & RSV (Liat), Luminex Aries® Flu A/B & RSV (Aries), and Diasorin SimplexaTM Flu A/B & RSV (Simplexa).
Padlock Probe Assay for Detection and Subtyping of Seasonal Influenza.
Clin Chem
December 2018
Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden;
Background: Influenza remains a constant threat worldwide, and WHO estimates that it affects 5% to 15% of the global population each season, with an associated 3 to 5 million severe cases and up to 500000 deaths. To limit the morbidity and the economic burden of influenza, improved diagnostic assays are needed.
Methods: We developed a multiplexed assay for the detection and subtyping of seasonal influenza based on padlock probes and rolling circle amplification.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!